RxDoctor Payments Data

Brianne Scanlon, OD

Optometrist · Oshkosh, WINPI 1245786300

Payments from drug & device makers

$2,539in general payments, 2019–2025

Across 119 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$549
  • Bausch & Lomb Americas Inc.$364
  • Novartis$264
  • Sun Pharmaceutical Industries Inc.$220
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$207
  • Rxsight Inc$153
  • plus $782 from 15 others

What the payments were for

  • Speaking & faculty fees$532%
  • Food & beverage$2,48698%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,539 in reported general payments places this provider in the 85th percentile of 867 optometrist providers in Wisconsin.

See all optometrist providers in Wisconsin

Medicare billing

Part B allowed, 2024
$38,221
Medicare patients
224
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine30$44,647
Cyclosporine23$16,605
MieboPerfluorohexyloctane/Pf14$13,281
Prednisolone Acetate168$6,199
LumiganBimatoprost12$3,851
CombiganBrimonidine Tartrate/Timolol14$3,439
Latanoprost223$2,631
Loteprednol Etabonate25$2,400
Bimatoprost14$2,176
Ketorolac Tromethamine73$1,847
Timolol Maleate65$1,716
Dorzolamide Hcl22$511
Ciprofloxacin Hcl36$387
Ofloxacin29$360
Brimonidine Tartrate26$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$549$51,93756 claims
Bausch & Lomb Americas Inc.Miebo$364$13,28114 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$207$2,40025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 867 optometrist providers in Wisconsin.

Other optometrist in Oshkosh

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →